Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

CAPP2 Investigators; John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop

doi:10.1016/S0140-6736(11)61049-0

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

CAPP2 Investigators, John Burn, Anne-Marie Gerdes, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Moeslein, Sylviane Olschwang, Diane Eccles, D Gareth Evans, Eamonn R Maher, Lucio Bertario, Marie-Luise Bisgaard, Malcolm G Dunlop, Judy W C Ho, Shirley V Hodgson, Annika Lindblom, Jan Lubinski, Patrick J Morrison, Victoria Murday, Raj RamesarLucy Side, Rodney J Scott, Huw J W Thomas, Hans F Vasen, Gail Barker, Gillian Crawford, Faye Elliott, Mohammad Movahedi, Kirsi Pylvanainen, Juul T Wijnen, Riccardo Fodde, Henry T Lynch, John C Mathers, D Timothy Bishop

Research output: Contribution to journal › Article › peer-review

Abstract

Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

Original language	English
Pages (from-to)	2081-7
Number of pages	7
Journal	The Lancet
Volume	378
Issue number	9809
DOIs	https://doi.org/10.1016/S0140-6736(11)61049-0
Publication status	Published - 2011

Access to Document

10.1016/S0140-6736(11)61049-0

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal
Copyright © 2011 Elsevier Ltd. All rights reserved. This document may be redistributed and reused
Accepted author manuscript, 321 KB

http://www.sciencedirect.com/science/article/pii/S0140673611610490

Cite this

CAPP2 Investigators, Burn, J., Gerdes, A.-M., Macrae, F., Mecklin, J.-P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D. G., Maher, E. R., Bertario, L., Bisgaard, M.-L., Dunlop, M. G., Ho, J. W. C., Hodgson, S. V., Lindblom, A., Lubinski, J., Morrison, P. J., Murday, V., ... Bishop, D. T. (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet, 378(9809), 2081-7. https://doi.org/10.1016/S0140-6736(11)61049-0

@article{2b9b372c89144e21a5e7bc5af92923fd,

title = "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial",

abstract = "Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.",

author = "\{CAPP2 Investigators\} and John Burn and Anne-Marie Gerdes and Finlay Macrae and Jukka-Pekka Mecklin and Gabriela Moeslein and Sylviane Olschwang and Diane Eccles and Evans, \{D Gareth\} and Maher, \{Eamonn R\} and Lucio Bertario and Marie-Luise Bisgaard and Dunlop, \{Malcolm G\} and Ho, \{Judy W C\} and Hodgson, \{Shirley V\} and Annika Lindblom and Jan Lubinski and Morrison, \{Patrick J\} and Victoria Murday and Raj Ramesar and Lucy Side and Scott, \{Rodney J\} and Thomas, \{Huw J W\} and Vasen, \{Hans F\} and Gail Barker and Gillian Crawford and Faye Elliott and Mohammad Movahedi and Kirsi Pylvanainen and Wijnen, \{Juul T\} and Riccardo Fodde and Lynch, \{Henry T\} and Mathers, \{John C\} and Bishop, \{D Timothy\}",

year = "2011",

doi = "10.1016/S0140-6736(11)61049-0",

language = "English",

volume = "378",

pages = "2081--7",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9809",

}

CAPP2 Investigators, Burn, J, Gerdes, A-M, Macrae, F, Mecklin, J-P, Moeslein, G, Olschwang, S, Eccles, D, Evans, DG, Maher, ER, Bertario, L, Bisgaard, M-L, Dunlop, MG, Ho, JWC, Hodgson, SV, Lindblom, A, Lubinski, J, Morrison, PJ, Murday, V, Ramesar, R, Side, L, Scott, RJ, Thomas, HJW, Vasen, HF, Barker, G, Crawford, G, Elliott, F, Movahedi, M, Pylvanainen, K, Wijnen, JT, Fodde, R, Lynch, HT, Mathers, JC & Bishop, DT 2011, 'Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial', The Lancet, vol. 378, no. 9809, pp. 2081-7. https://doi.org/10.1016/S0140-6736(11)61049-0

TY - JOUR

T1 - Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer

T2 - an analysis from the CAPP2 randomised controlled trial

AU - CAPP2 Investigators

AU - Burn, John

AU - Gerdes, Anne-Marie

AU - Macrae, Finlay

AU - Mecklin, Jukka-Pekka

AU - Moeslein, Gabriela

AU - Olschwang, Sylviane

AU - Eccles, Diane

AU - Evans, D Gareth

AU - Maher, Eamonn R

AU - Bertario, Lucio

AU - Bisgaard, Marie-Luise

AU - Dunlop, Malcolm G

AU - Ho, Judy W C

AU - Hodgson, Shirley V

AU - Lindblom, Annika

AU - Lubinski, Jan

AU - Morrison, Patrick J

AU - Murday, Victoria

AU - Ramesar, Raj

AU - Side, Lucy

AU - Scott, Rodney J

AU - Thomas, Huw J W

AU - Vasen, Hans F

AU - Barker, Gail

AU - Crawford, Gillian

AU - Elliott, Faye

AU - Movahedi, Mohammad

AU - Pylvanainen, Kirsi

AU - Wijnen, Juul T

AU - Fodde, Riccardo

AU - Lynch, Henry T

AU - Mathers, John C

AU - Bishop, D Timothy

PY - 2011

Y1 - 2011

N2 - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

AB - Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.

UR - https://www.scopus.com/pages/publications/83955161674

U2 - 10.1016/S0140-6736(11)61049-0

DO - 10.1016/S0140-6736(11)61049-0

M3 - Article

C2 - 22036019

SN - 1474-547X

VL - 378

SP - 2081

EP - 2087

JO - The Lancet

JF - The Lancet

IS - 9809

ER -

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this